We are pleased to announce that Cancer Immunology, Immunotherapy (CII) will become a fully open access (OA) journal in 2024. As a result, all submissions received from 1st August 2023 are subject to an article publication charge (APC) if accepted and published in the journal (unless a waiver is applied). Please see our FAQs which can be found at the bottom of this page for more information on APCs, funding options, waivers and the journal's transition to fully open access.
We will therefore only be accepting submissions that will be published open access.
See journal updates below for more information.
Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms.
CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT).
SEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&Upfqym5uom=GKCITIM: http://www.canceritim.org
This is a transformative journal, you may have access to funding.
We are excited to announce that Cancer Immunology, Immunotherapy will become a fully open access (OA) journal in 2024. This means that as of January 2024, we will only be publishing open access articles, meaning content will be freely available to readers worldwide, enabling the widest possible dissemination and reuse.
Springer Nature is committed to ensuring our portfolios serve and meet the evolving needs of the research community and that quality research is read and disseminated as widely as possible. Transforming Cancer Immunology, Immunotherapy to full OA reflects our ongoing commitment to driving the transition to open research, and providing researchers with OA publication venues that can amplify their research and enable compliance with funder and institutional OA requirements while continuing to deliver a high level of author service. See our FAQs for further information.
Frequently asked questions regarding the transition to fully open access and what this means for the Cancer Immunology, Immunotherapy
Sign up for free online attendance.
Discover the range of academic oncology titles at Springer Nature here.